CD8A and neoplasm: Recent preclinical and clinical studies have indicated that RT combined with PD-1/PD-L1 inhibitors may enhance the immune function and recover the CD8+ T-cell activity, thereby inhibiting tumor growth and increasing patient survival considerably (Table 1) [41].